Oncolytics Biotech Announces New Clinical Trial for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
I'm PortAI, I can summarize articles.
Oncolytics Biotech Inc. announced new clinical trial for pelareorep in KRAS-mutant metastatic colorectal cancer. Promising data shows 33% overall response rate in this patient subgroup. The company plans a controlled clinical study to further evaluate efficacy, aiming to support future regulatory submissions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments